1GEHC Stock Chart & Stats
€54.95
€7.58(13.79%)
At close: 4:00 PM EDT
€54.95
€7.58(13.79%)
Day’s Range― - ―
52-Week Range€29.00 - €111.00
Previous CloseN/A
Volume175.00
Average Volume (3M)31.00
Market Cap
€27.39B
Enterprise Value€37.74B
Total Cash (Recent Filing)€2.10B
Total Debt (Recent Filing)€10.09B
Price to Earnings (P/E)19.5
Beta0.71
Next Earnings
Oct 28, 2026EPS Estimate
1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.48
Shares Outstanding451,686,250
10 Day Avg. Volume63
30 Day Avg. Volume31
Financial Highlights & Ratios
PEG Ratio4.14
Price to Book (P/B)3.61
Price to Sales (P/S)1.82
P/FCF Ratio24.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€71.18Price Target Upside29.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)4.41
Revenue Forecast (FY)€19.44B
Bulls Say, Bears Say
Bulls Say
Record Backlog And Demand VisibilityStrong order growth, a book-to-bill ratio above one, and a record backlog provide meaningful forward revenue visibility. These indicators suggest continued customer demand and support more predictable equipment activity over the next several quarters, despite uneven segment performance.
Service Revenue Provides Recurring SupportService revenue growth adds a recurring element to GE HealthCare’s equipment-led model, because its installed base requires maintenance, repairs, upgrades, and support. This can make revenue more resilient over time and help offset variability in capital equipment purchasing cycles.
Pharmaceutical Diagnostics Growth And InnovationPharmaceutical Diagnostics is showing strong growth with high segment profitability, while expanding Flyrcado usage demonstrates progress in a newer offering. Continued adoption could diversify the portfolio and create a durable growth contribution beyond traditional equipment sales.
Bears Say
Patient Care Solutions Structural WeaknessThe strategic review and negative profitability indicate that Patient Care Solutions is more than a minor quarterly issue. A potential sale or restructuring could require management attention, disrupt the portfolio, and leave GE HealthCare dependent on successful recovery actions.
Free Cash Flow Is WeakeningA sharp decline in trailing free cash flow reduces the funds available for debt reduction, shareholder returns, and internal investment. Although cash generation remains positive, weaker conversion can constrain financial flexibility and make execution of growth plans more dependent on improvement.
Margin Pressure From Inflation And PCSCompany-wide margin compression shows that operational problems and higher component, freight, oil, and memory costs are offsetting gains elsewhere. If these pressures persist, they can limit earnings growth and make management’s planned margin expansion harder to achieve.
GE Healthcare Technologies Inc News
1GEHC FAQ
What was GE Healthcare Technologies Inc’s price range in the past 12 months?
GE Healthcare Technologies Inc lowest stock price was €29.00 and its highest was €111.00 in the past 12 months.
What is GE Healthcare Technologies Inc’s market cap?
GE Healthcare Technologies Inc’s market cap is €27.39B.
When is GE Healthcare Technologies Inc’s upcoming earnings report date?
GE Healthcare Technologies Inc’s upcoming earnings report date is Oct 28, 2026 which is in 14 days.
How were GE Healthcare Technologies Inc’s earnings last quarter?
GE Healthcare Technologies Inc released its earnings results on Jul 29, 2026. The company reported €1.012 earnings per share for the quarter, beating the consensus estimate of €0.928 by €0.084.
Is GE Healthcare Technologies Inc overvalued?
According to Wall Street analysts GE Healthcare Technologies Inc’s price is currently Undervalued.
Does GE Healthcare Technologies Inc pay dividends?
GE Healthcare Technologies Inc does not currently pay dividends.
What is GE Healthcare Technologies Inc’s EPS estimate?
GE Healthcare Technologies Inc’s EPS estimate is 1.08.
How many shares outstanding does GE Healthcare Technologies Inc have?
GE Healthcare Technologies Inc has 451,686,250 shares outstanding.
What happened to GE Healthcare Technologies Inc’s price movement after its last earnings report?
GE Healthcare Technologies Inc reported an EPS of €1.012 in its last earnings report, beating expectations of €0.928. Following the earnings report the stock price went up 13.794%.
Which hedge fund is a major shareholder of GE Healthcare Technologies Inc?
Currently, no hedge funds are holding shares in IT:1GEHC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GE Healthcare Technologies Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€71.18 (29.53% Upside)
€71.18 (29.53% Upside)
Blogger Sentiment
Bullish
IT:1GEHC Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.42%
12-Months-Change
Fundamentals
Return on Equity
15.16%
Trailing 12-Months
Asset Growth
4.92%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GE Healthcare Technologies Inc
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
1GEHC Company Deck
1GEHC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call showed strong commercial momentum: record orders, backlog, solid revenue growth, PDx outperformance, AIS margin expansion, and progress on new AI-enabled products and Flyrcado ramp. Offsetting these positives were meaningful near-term challenges in Patient Care Solutions (13.5% organic decline and negative segment EBIT), inflationary headwinds (memory, oil, freight), and cash volatility driven by tariff refunds. Management maintained full-year guidance and reiterated medium-term targets, expressing confidence in recovery actions and the innovation pipeline.View all IT:1GEHC earnings summaries1GEHC Revenue Breakdown
44.82% Imaging
25.96% AVS
14.96% PCS
14.06% PDx
0.19% Other

1GEHC Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€71.18
▲(29.53% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Koninklijke Philips
―
Medtronic
―












